Linked Life Data

17704480

Source:http://linkedlifedata.com/resource/pubmed/id/17704480

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-8-20
pubmed:abstractText
Three thoracic endograft devices have concluded their phase II trials for release in the United States. The Gore TAG endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz) was the first to enter clinical trials for the treatment of thoracic aortic aneurysms, confirming its safety and efficacy as well as its short-term advantages over open surgical repair. In March 2005, it became the first endograft to gain United States Food and Drug Administration approval for general use. Follow-up in the Gore TAG pivotal trial demonstrates that aneurysm-related mortality is improved compared with open surgical repair, with similar overall mortality and reintervention rates.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1531-0035
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
124-30
pubmed:dateRevised
2008-4-23
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Mid-term results of a multicenter study of thoracic endovascular aneurysm repair versus open repair.
pubmed:affiliation
Division of Vascular Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
pubmed:publicationType
Journal Article, Comparative Study, Multicenter Study